ES-SCLC Patients with PD-L1⁺ CTCs and High Percentages of CD8⁺PD-1⁺T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

SCLC is an aggressive cancer type with high metastatic potential and bad prognosis. CTCs are a valuable source of tumor cells in blood circulation and are among the major contributors to metastasis. In this study we evaluated the number of CTCs that express PD-L1 in treatment-naïve ES-SCLC patients...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Anastasia Xagara, Argyro Roumeliotou, Alexandros Kokkalis, Konstantinos Tsapakidis, Dimitris Papakonstantinou, Vassilis Papadopoulos, Ioannis Samaras, Evagelia Chantzara, Galatea Kallergi, Athanasios Kotsakis
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2024-01-01
Edice:	Biomedicines
Témata:	ES-SCLC CTCs PD-L1<sup>+</sup>CTCs CD8<sup>+</sup> T-cells PD-1<sup>+</sup> T-cells ICI therapy
On-line přístup:	https://www.mdpi.com/2227-9059/12/1/146
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!